Bionor Pharma is a leading vaccine company, searching for breakthrough treatments for HIV and other deadly viruses.

Latest news

Hide mandatory notifications of trade

Share capital increase registered

Financial .2015

(Oslo, Norway, 23 June 2015) With reference to the announcement made on 18 June 2015 regarding issuance of shares to former employee Birger Sørensen under a share option agreement, the share capital increase has now been registered in the Companies Register.

Exercise of share options

Financial .2015

(Oslo, Norway, 18 June 2015) The Board of Directors of Bionor Pharma ASA (OSE:BIONOR) has resolved to issue 666,667 new shares in the Company based on options exercised by former employee Birger Sørensen.

Bionor appoints new Chairman and three Non-Executive Directors

Financial .2015

(Oslo, Norway, 13 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV announces, following today’s Annual General Meeting, the appointment of a new Chairman and three Non-Executive Directors.

Share capital increase registered

Financial .2015

(Oslo, Norway, 23 June 2015) With reference to the announcement made on 18 June 2015 regarding issuance of shares to former employee Birger Sørensen under a share option agreement, the share capital increase has now been registered in the Companies Register.

Bionor Pharma ASA issues shares to board members

Financial .2015

(Oslo, Norway, 23 June 2015) In accordance with the resolution by the Annual General Meeting of Bionor Pharma ASA (OSE: BIONOR) on 13 May 2015, all board members have been offered to subscribe shares in the Company valued at NOK 100,000 and the Chairman of the Board has been offered to subscribe shares valued at NOK 200,000.

Exercise of share options

Financial .2015

(Oslo, Norway, 18 June 2015) The Board of Directors of Bionor Pharma ASA (OSE:BIONOR) has resolved to issue 666,667 new shares in the Company based on options exercised by former employee Birger Sørensen.

Go to news section

Featured content